Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Tukysa (tucatinib by Year
Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — U.S. revenues ($M) ($M)
Pfizer Tukysa (tucatinib: $352M in FY2025, down 9.5% from a year earlier.
Where the FY2025 figure comes from
“|| Tukysa | 463 | 480 | (4%) | (4%) | 352 | 389 | (10%) | 111 | 91 | 22% | 18%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 352 | -9.5% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 389 | +2,061.1% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 18 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
Breakdown
What makes up tukysa (tucatinib
Cite this data
StockData. (2026). Pfizer Tukysa (tucatinib ($M), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/tukysa-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.